Preliminary results of a first-in-human, first-in-class phase I study of MTL-CEBPA, a small activating RNA (saRNA) targeting the transcription factor C/EBP-α in patients with advanced liver cancer.

Authors

Debashis Sarker

King's College London, London, United Kingdom

Debashis Sarker , Elizabeth Ruth Plummer , Bristi Basu , Tim Meyer , Kai-Wen Huang , T.R. Jeffry Evans , Duncan Spalding , Yuk Ting Ma , Daniel H. Palmer , Cheng Ean Chee , Nagy A Habib

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2017 ASCO Annual Meeting

bookmark_border

First-in-human, first-in-class phase I study of MTL-CEBPA, a small activating RNA (saRNA) targeting the transcription factor C/EBP-α in patients with advanced liver cancer.

First Author: Debashis Sarker

insert_chart_outlined

Poster

2013 Gastrointestinal Cancers Symposium

bookmark_border

Characteristics and outcomes of patients with advanced hepatocellular carcinoma treated on phase I trials.

First Author: Ishwaria Subbiah

insert_chart_outlined

Poster

2011 ASCO Annual Meeting

bookmark_border

MLN4924, an investigational NEDD8-activating enzyme (NAE) inhibitor, in patients (pts) with advanced solid tumors: Phase I study of multiple treatment schedules.

First Author: J. S. Kauh

insert_chart_outlined

Poster

2024 ASCO Annual Meeting

bookmark_border

An open-label, multicenter phase 1 study to characterize safety, tolerability, preliminary antitumor activity, and pharmacokinetics of VIP236 monotherapy in patients with advanced cancer.

First Author: Andrae L. Vandross